Hypofractionated Online Adaptive Radiotherapy of Breast Cancer

Summary

The goal of this clinical trial is to explore the application of online adaptive radiotherapy in patients who receive moderate hypofractionated or ultrafractionated radiotherapy after breast cancer surgery. The main questions it aims to answer are: * Can online adaptive radiotherapy improve the accuracy of dose delivery? * In patients undergoing online adaptive radiotherapy, how are the treatment-related toxicities and tumor control outcomes? Participants will Receive moderate hypofractionated radiotherapy using online adaptive radiotherapy, a dose of 43.5Gy in 15 fractions or receive ultrafractionated radiotherapy using online adaptive radiotherapy, a dose of 26Gy in 5 fractions.

Eligibility

Inclusion Criteria:

* Female, aged ≥35 years, \<70 years
* ECOG score: 0-2
* Having underwent breast-conserving surgery or Modified radical mastectomy with or without sentinel lymph node biopsy or axillary lymph node dissection
* Pathologically confirmed primary breast cancer
* For patients who did not receive neoadjuvant therapy: pathological staged pT0-2N0-1; for patients who received neoadjuvant therapy: staged ypT0-2N0-1
* Indicated for postoperative adjuvant radiotherapy, planned to undergo postoperative adjuvant radiotherapy
* Able to cooperate and tolerate the treatment

Exclusion Criteria:

* Pathologically confirmed metastasis in supraclavicular or infraclavicular lymph nodes, or distant metastasis
* History of radiotherapy to the neck or chest
* Contraindications or intolerance to radiation therapy (such as pregnancy or lactation, severe impairment of heart, lung, kidney, liver, or other vital organ functions; severe infection or hematologic abnormalities; brachial plexus nerve injury on the affected side; active connective tissue diseases, etc.)
* History of malignant tumors

Conditions2

Browse More Trials